Trial Profile
A Phase I, Dose Escalation Study to Assess the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, With and Without Trastuzumab in Subjects With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Carboplatin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK; Novartis Pharmaceuticals
- 06 Dec 2019 Status changed from active, no longer recruiting to completed.
- 29 Aug 2019 Planned End Date changed from 28 Jun 2019 to 30 Sep 2019.
- 14 May 2019 Planned End Date changed from 31 Dec 2019 to 28 Jun 2019.